Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates

By Boon L.   Holland B.   Gordon W.   Liu P.   Shiau F.   Shanahan W.   Reimann K.A.   Fung M.  

Toxicology, Vol. 172, Iss. 3, 2002-04 ,pp. : 191-203

Elsevier

Access to resources Recommend Favorite

Cynomolgus monkeys (Macaca fascicularis) in preclinical immune function safety testing: development of a delayed-type hypersensitivity procedure

By Bleavins M.R.   de la Iglesia F.A.  

Toxicology, Vol. 95, Iss. 1, 1995-01 ,pp. : 103-112

Elsevier

Access to resources Recommend Favorite

Anti-CD40 Treatment of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-Exposed C57Bl/6 Mice Induces Activation of Antigen Presenting Cells Yet Fails to Overcome TCDD-Induced Suppression of Allograft Immunity

By Shepherd D.M.   Steppan L.B.   Hedstrom O.R.   Kerkvliet N.I.  

Toxicology and Applied Pharmacology, Vol. 170, Iss. 1, 2001-01 ,pp. : 10-22

Elsevier

Access to resources Recommend Favorite

Preclinical Assessment of Vernonia amygdalina Leaf Extracts as DNA Damaging Anti-cancer Agent in the Management of Breast Cancer

By Yedjou Clement   Izevbigie Ernest   Tchounwou Paul  

International Journal of Environmental Research and Public Health, Vol. 5, Iss. 5, 2008-12 ,pp. : 337-341

MDPI

Access to resources Recommend Favorite

Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced decrease in anti-CD3-activated CD4 + T cells: the roles of apoptosis, Fas, and TNF

By Dearstyne E.A.   Kerkvliet N.I.  

Toxicology, Vol. 170, Iss. 1, 2002-01 ,pp. : 139-151

Elsevier

Access to resources Recommend Favorite